儿科创伤性脑损伤和长期使用抗抑郁药:全国性的基于登记的队列研究
Juho Laaksonen1, Ville Ponkilainen2, Julius Möttönen1
1Tampereen yliopisto Laaketieteen ja terveysteknologian tiedekunta, Tampere, Pirkanmaa, Finland.
Acta paediatrica (Oslo, Norway : 1992)
|June 3, 2025
概括
患有儿科创伤性脑损伤 (pTBI) 的儿童使用抗抑郁药物的风险增加,特别是在手术后和女性. 这种高风险在受伤后的9年内持续存在.
科学领域:
- 神经科学是一个神经科学.
- 公共卫生 公共卫生
- 儿科 儿科 儿科
背景情况:
- 儿科创伤性脑损伤 (pTBI) 是一个重大的健康问题.
- 对pTBI的长期心理健康后果,特别是抗抑郁药的使用,尚不清楚.
研究的目的:
- 调查儿科创伤性脑损伤 (pTBI) 与随后使用抗抑郁药物的相关性.
- 确定儿科患者中创伤后抗抑郁药使用的风险因素和时间趋势.
主要方法:
- 一项全国性的芬兰回顾性队列研究 (1998-2018) 分析了来自71,969名pTBI患者和64,856名对照者的数据.
- 对抗抑郁药物的数据是从芬兰社会保险机构获得的.
- 卡普兰-梅尔分析和考克斯回归被用来确定创伤后儿科抗抑郁药使用的主要结果.
主要成果:
- 与对照组相比,抗抑郁药使用的累积发病率在pTBI患者中较高,在20年内显著增加.
- 考克斯回归显示,在pTBI患者中,抗抑郁药使用的长期风险更高 (HR 1.31至9年).
- 经过手术治疗的pTBI的风险明显更高 (2年后HR4.45),女性比男性 (HR1.54) 的风险更大 (1年后HR2.60).
结论:
- 在儿童创伤性脑损伤 (pTBI) 后,抗抑郁药的使用显著增加,特别是在第一年后.
- 这种风险在女性和接受手术治疗的人群中尤为明显.
- 这种使用抗抑郁药物的风险增加在pTBI后持续长达9年,突出了长期心理健康监测的必要性.
相关概念视频
Long-term Depression
33.2K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
33.2K
Long-term Depression
3.1K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
3.1K
Antidepressant Drugs: Overview
1.4K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.4K
Antidepressant Drugs: MAOIs and Other Agents
831
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
831
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
1.4K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.4K


